IL161587A0 - Pharmaceutical containing 3 (3-dimethylamino-1-ethyl-2-methyl-propyl) phenol and providing delayed release of the active ingredient - Google Patents

Pharmaceutical containing 3 (3-dimethylamino-1-ethyl-2-methyl-propyl) phenol and providing delayed release of the active ingredient

Info

Publication number
IL161587A0
IL161587A0 IL16158702A IL16158702A IL161587A0 IL 161587 A0 IL161587 A0 IL 161587A0 IL 16158702 A IL16158702 A IL 16158702A IL 16158702 A IL16158702 A IL 16158702A IL 161587 A0 IL161587 A0 IL 161587A0
Authority
IL
Israel
Prior art keywords
dimethylamino
phenol
propyl
ethyl
methyl
Prior art date
Application number
IL16158702A
Other languages
English (en)
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26010444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL161587(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE10152469A external-priority patent/DE10152469A1/de
Priority claimed from DE2002148309 external-priority patent/DE10248309A1/de
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of IL161587A0 publication Critical patent/IL161587A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IL16158702A 2001-10-24 2002-10-22 Pharmaceutical containing 3 (3-dimethylamino-1-ethyl-2-methyl-propyl) phenol and providing delayed release of the active ingredient IL161587A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10152469A DE10152469A1 (de) 2001-10-24 2001-10-24 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung
DE2002148309 DE10248309A1 (de) 2002-10-16 2002-10-16 3-(3- Dimethylamino-1-ethyl-2-methyl-propyl) phenol enthaltendes Arzeimittel mit verzögerter Wirkstofffreisetzung
PCT/EP2002/011809 WO2003035053A1 (de) 2001-10-24 2002-10-22 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes arzneimittel mit verzögerter wirkstofffreisetzung

Publications (1)

Publication Number Publication Date
IL161587A0 true IL161587A0 (en) 2004-09-27

Family

ID=26010444

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16158702A IL161587A0 (en) 2001-10-24 2002-10-22 Pharmaceutical containing 3 (3-dimethylamino-1-ethyl-2-methyl-propyl) phenol and providing delayed release of the active ingredient
IL161587A IL161587A (en) 2001-10-24 2004-04-22 Pharmaceutical composition containing 3 - (3 - dimethylamino - 1 - ethyl - 2 - methyl - propyl) phenol and providing delayed release of the active ingredient

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL161587A IL161587A (en) 2001-10-24 2004-04-22 Pharmaceutical composition containing 3 - (3 - dimethylamino - 1 - ethyl - 2 - methyl - propyl) phenol and providing delayed release of the active ingredient

Country Status (28)

Country Link
US (7) US20050058706A1 (cg-RX-API-DMAC7.html)
EP (1) EP1439829B1 (cg-RX-API-DMAC7.html)
JP (2) JP4758064B2 (cg-RX-API-DMAC7.html)
KR (1) KR100958045B1 (cg-RX-API-DMAC7.html)
CN (1) CN100402021C (cg-RX-API-DMAC7.html)
AR (1) AR036943A1 (cg-RX-API-DMAC7.html)
AT (1) ATE303802T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002349001C1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0213653B8 (cg-RX-API-DMAC7.html)
CA (1) CA2464578C (cg-RX-API-DMAC7.html)
CO (1) CO5570662A2 (cg-RX-API-DMAC7.html)
CY (1) CY2012022I2 (cg-RX-API-DMAC7.html)
DE (1) DE50204198D1 (cg-RX-API-DMAC7.html)
DK (1) DK1439829T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP045102A (cg-RX-API-DMAC7.html)
ES (1) ES2248622T3 (cg-RX-API-DMAC7.html)
HU (1) HU230161B1 (cg-RX-API-DMAC7.html)
IL (2) IL161587A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04003742A (cg-RX-API-DMAC7.html)
MY (1) MY127797A (cg-RX-API-DMAC7.html)
NO (2) NO331896B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ532999A (cg-RX-API-DMAC7.html)
PE (1) PE20030527A1 (cg-RX-API-DMAC7.html)
PL (1) PL216535B1 (cg-RX-API-DMAC7.html)
PT (1) PT1439829E (cg-RX-API-DMAC7.html)
SI (1) SI1439829T1 (cg-RX-API-DMAC7.html)
WO (2) WO2003035054A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200403928B (cg-RX-API-DMAC7.html)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
ES2819854T3 (es) 2002-11-22 2021-04-19 Gruenenthal Gmbh Uso de (1R,2R)-3-(3-dimetilamino-1-etil-2-metil-propil)-fenol para tratar el dolor inflamatorio
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US20070183980A1 (en) * 2003-08-06 2007-08-09 Elisabeth Arkenau-Maric Dosage form that is safeguarded from abuse
DE10336400A1 (de) * 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) * 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
ATE368639T1 (de) 2004-06-28 2007-08-15 Gruenenthal Gmbh Kristalline formen von (-)-(1r,2r)-3-(3- dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochlorid
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
WO2006002886A1 (de) * 2004-07-01 2006-01-12 Grünenthal GmbH Gegen missbrauch gesicherte, orale darreichungsform enthaltend (1r, 2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
NZ571939A (en) * 2006-04-28 2011-10-28 Gruenenthal Chemie Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and an NSAID
JP5496653B2 (ja) * 2006-04-28 2014-05-21 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ３−（３−ジメチルアミノ−１−エチル−２−メチル−プロピル）−フェノール、およびパラセタモールを含む医薬の組合せ
CN101091725A (zh) * 2006-06-23 2007-12-26 天津天士力制药股份有限公司 一种中药颗粒及其制备方法
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007011485A1 (de) * 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
EP1985292A1 (en) * 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
DE102007019417A1 (de) 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol zur Schmerzbehandlung bei Arthrose
NZ586361A (en) * 2007-11-23 2012-09-28 Gruenenthal Chemie Tapentadol compositions
PT2240431T (pt) * 2007-12-07 2017-05-03 Gruenenthal Gmbh Modificações cristalinas de (1r,2r)-3-(3-dimetilamino-1- etil-2-metil-propil)fenol
EP2249811A1 (en) * 2008-01-25 2010-11-17 Grünenthal GmbH Pharmaceutical dosage form
KR101690094B1 (ko) 2008-05-09 2016-12-27 그뤼넨탈 게엠베하 분무 응결 단계의 사용하에 중간 분말 제형 및 최종 고체 제형을 제조하는 방법
US20100190752A1 (en) * 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
AU2009340504A1 (en) 2008-10-30 2010-08-26 Grunenthal Gmbh Novel and potent tapentadol dosage forms
SI2456424T1 (sl) 2009-07-22 2013-10-30 Gruenenthal Gmbh Oksidacijsko stabilizirana odmerna oblika, varna pred zlorabo
AR077493A1 (es) 2009-07-22 2011-08-31 Gruenenthal Gmbh Composicion farmaceutica extruida en caliente con liberacion controlada. procedimiento de preparacion
EP2531176B1 (en) * 2010-02-03 2016-09-07 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of an extruder
CA2832436C (en) 2010-04-07 2018-08-14 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
US20130116333A1 (en) * 2010-05-05 2013-05-09 Ratiopharm Gmbh Solid tapentadol in non-crystalline form
AU2011267474B2 (en) * 2010-06-15 2016-05-26 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
AU2011273907B2 (en) 2010-06-30 2015-03-19 Grunenthal Gmbh Tapentadol for use in the treatment of Irritable Bowel Syndrome
DK3656765T3 (da) 2010-07-23 2021-06-14 Gruenenthal Gmbh Salte eller co-krystaller af 3-(3-dimethylamin-1-ethyl-2-methyl-propyl)-phenol
PL2611425T3 (pl) 2010-09-02 2014-09-30 Gruenenthal Gmbh Odporna na ingerencję postać dawki zawierająca polimer anionowy
MX2013002377A (es) 2010-09-02 2013-04-29 Gruenenthal Gmbh Forma de dosificacion resistente a manipulacion que comprende una sal inorganica.
EP2680833B1 (en) 2011-03-04 2016-03-02 Grünenthal GmbH Parenteral administration of tapentadol
BR112013022556A8 (pt) 2011-03-04 2018-01-16 Gruenenthal Gmbh composição farmacêutica aquosa semissólida contendo tapentadol, seu uso e uso de tapentadol
LT3287123T (lt) 2011-03-04 2020-06-10 Grünenthal GmbH Vandeninė farmacinė tapentadolio kompozicija, skirta gerti
WO2012136351A1 (en) 2011-04-05 2012-10-11 Grünenthal GmbH Tapentadol for treating pain associated with trigeminal neuralgia
PT2694049T (pt) 2011-04-05 2019-02-06 Gruenenthal Gmbh Tapentadol para prevenir a cronicidade da dor
ES2646363T3 (es) 2011-04-29 2017-12-13 Grünenthal GmbH Tapentadol para la prevención y el tratamiento de la depresión y la ansiedad
WO2013017233A1 (en) * 2011-07-29 2013-02-07 Grünenthal GmbH Intrathecal or epidural administration of 3-[(1s,2s)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol
JP2014524925A (ja) 2011-07-29 2014-09-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時薬剤放出を提供するタンパーレジスタント錠剤
EP2736497B1 (en) 2011-07-29 2017-08-23 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
EP2606879A1 (en) 2011-12-21 2013-06-26 Hexal AG Multiple unit pellet tablet formulation comprising an opioid
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
AR090695A1 (es) 2012-04-18 2014-12-03 Gruenenthal Gmbh Forma de dosificacion farmaceutica resistente a la adulteracion y resistente a la liberacion inmediata de la dosis
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
MX371432B (es) 2013-05-29 2020-01-30 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido que contiene una o mas particulas.
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
EA032465B1 (ru) 2013-07-12 2019-05-31 Грюненталь Гмбх Защищенная от применения не по назначению пероральная фармацевтическая лекарственная форма, содержащая этиленвинилацетатный полимер, и способ ее изготовления
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
WO2015071248A1 (en) 2013-11-15 2015-05-21 Synthon B.V. Abuse-proofed extended release pharmaceutical composition comprising tapentadol
BR112016010482B1 (pt) 2013-11-26 2022-11-16 Grünenthal GmbH Preparação de uma composição farmacêutica em pó por meio de criomoagem
EP2942054A1 (en) * 2014-05-09 2015-11-11 G.L. Pharma GmbH Slow-release pharmaceutical formulation
MX2016014738A (es) 2014-05-12 2017-03-06 Gruenenthal Gmbh Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol.
MX2016015417A (es) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticulas protegidas contra vertido de dosis etanolico.
EA036258B1 (ru) 2015-03-27 2020-10-20 Грюненталь Гмбх Стабильный препарат для парентерального введения тапентадола
EA035434B1 (ru) 2015-04-24 2020-06-15 Грюненталь Гмбх Защищенная от применения не по назначению лекарственная форма с немедленным высвобождением и устойчивостью к экстракции растворителями
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
EP3231420A1 (en) 2016-02-29 2017-10-18 G.L. Pharma GmbH Abuse-deterrent pharmaceutical compositions
WO2018055070A1 (en) 2016-09-23 2018-03-29 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
WO2018153947A1 (en) 2017-02-23 2018-08-30 Grünenthal GmbH Tapentadol as local anesthetic
WO2018219897A1 (en) * 2017-05-29 2018-12-06 Grünenthal GmbH Multiparticulate oral dosage form providing prolonged release of tapentadol
WO2021175773A1 (en) 2020-03-02 2021-09-10 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt
EP3875079A1 (en) * 2020-03-02 2021-09-08 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt
EP3875077B1 (en) * 2020-03-02 2023-12-13 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt
AU2020100442B4 (en) * 2020-03-02 2020-06-18 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt
AU2020100441B4 (en) * 2020-03-02 2020-06-18 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt
ES3010208T3 (en) * 2020-03-16 2025-04-01 Gruenenthal Gmbh Scored tablet comprising tapentadol
DE202020104285U1 (de) 2020-07-24 2020-12-18 Grünenthal GmbH Ethylcellulose-beschichtete Partikel enthaltend ein Salz aus Tapentadol und Phosphorsäure
HUE059465T2 (hu) 2020-11-10 2022-11-28 Gruenenthal Gmbh A tapentadol L-(+)- borkõsav-só késleltetett felszabadulású adagolási formája
DE202020005470U1 (de) 2020-11-10 2022-01-25 Grünenthal GmbH Darreichungsformen mit verlängerter Freisetzung eines Salzes von Tapentadol mit L-(+)-Weinsäure
WO2022101247A1 (de) 2020-11-10 2022-05-19 Grünenthal GmbH Darreichungsformen mit verlängerter freisetzung eines salzes von tapentadol mit l-(+)-weinsäure

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
DE2117239A1 (de) 1971-04-08 1972-11-16 König, Wilhelm, 4712 Werne Verfahren zum Erstellen von Wänden aus Schalungssteinen
US4126672A (en) * 1976-02-04 1978-11-21 Hoffmann-La Roche Inc. Sustained release pharmaceutical capsules
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US5688645A (en) 1983-01-10 1997-11-18 Gen-Probe Incorporated Method for detecting, identifying, and quantitating non-viral organisms
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
GB8519310D0 (en) 1985-07-31 1985-09-04 Zyma Sa Granular active substances
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
DK0661045T3 (da) * 1992-09-18 2002-10-28 Yamanouchi Pharma Co Ltd Hydrogelpræparat med forsinket frigivelse
IL109460A (en) * 1993-05-10 1998-03-10 Euro Celtique Sa Controlled release formulation comprising tramadol
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
DE4329794C2 (de) 1993-09-03 1997-09-18 Gruenenthal Gmbh Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung
ES2201092T3 (es) 1993-11-17 2004-03-16 Lequio Pharma Co., Ltd. Composicion para curar tejido lesionado, procedimiento para preparar la misma y uso de la misma.
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
CN1125572A (zh) * 1994-12-28 1996-07-03 顺德市广容制药厂 一种罗通定痛释片的制作方法
IL139728A (en) * 1995-01-09 2003-06-24 Penwest Pharmaceuticals Compan Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient
DE19525137C2 (de) 1995-07-11 2003-02-27 Gruenenthal Gmbh 6-Dimethylaminomethyl-1-phenyl-cyclohexanverbin -dungen als Zwischenprodukte zur Herstellung pharmazeutischer Wirkstoffe
DE19609847A1 (de) 1996-03-13 1997-09-18 Gruenenthal Gmbh Dimethyl-(3-aryl-but-3-enyl)-aminverbindungen als pharmazeutische Wirkstoffe
US6096339A (en) 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
KR100321489B1 (ko) * 1996-07-08 2002-10-09 에드워드 멘델 컴파니 인코포레이티드 고용량의불용성약물용서방성매트릭스
DE19630035A1 (de) * 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
AU729529B2 (en) * 1997-06-06 2001-02-01 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6106862A (en) * 1998-08-13 2000-08-22 Andrx Corporation Once daily analgesic tablet
DE19901683B4 (de) 1999-01-18 2005-07-21 Grünenthal GmbH Analgetikum mit kontrollierter Wirkstofffreisetzung
EP1623703B1 (en) * 1999-10-29 2011-10-05 Euro-Celtique S.A. Controlled release hydrocodone formulations
DE10109763A1 (de) 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
DE10248309A1 (de) 2002-10-16 2004-04-29 Grünenthal GmbH 3-(3- Dimethylamino-1-ethyl-2-methyl-propyl) phenol enthaltendes Arzeimittel mit verzögerter Wirkstofffreisetzung

Also Published As

Publication number Publication date
AR036943A1 (es) 2004-10-13
JP2005506367A (ja) 2005-03-03
US20170087103A1 (en) 2017-03-30
WO2003035054A1 (de) 2003-05-01
PL369756A1 (en) 2005-05-02
US20130237608A1 (en) 2013-09-12
NO331896B1 (no) 2012-04-30
CN100402021C (zh) 2008-07-16
HK1068539A1 (en) 2005-04-29
DK1439829T3 (da) 2005-10-10
SI1439829T1 (sl) 2006-02-28
US11007156B2 (en) 2021-05-18
ES2248622T3 (es) 2006-03-16
NO20041924L (no) 2004-05-11
KR100958045B1 (ko) 2010-05-17
BRPI0213653B1 (pt) 2018-04-03
DE50204198D1 (de) 2005-10-13
CO5570662A2 (es) 2005-10-31
NZ532999A (en) 2007-06-29
US20120034304A1 (en) 2012-02-09
CN1607947A (zh) 2005-04-20
WO2003035053A1 (de) 2003-05-01
US20180221308A1 (en) 2018-08-09
CA2464578A1 (en) 2003-05-01
ATE303802T1 (de) 2005-09-15
BRPI0213653B8 (pt) 2021-05-25
EP1439829B1 (de) 2005-09-07
JP2010280697A (ja) 2010-12-16
MXPA04003742A (es) 2004-07-23
ZA200403928B (en) 2005-07-27
NO2012007I1 (no) 2012-05-21
US20050058706A1 (en) 2005-03-17
HUP0402104A2 (hu) 2005-03-29
AU2002349001B2 (en) 2003-05-06
AU2002349001C1 (en) 2022-04-14
PE20030527A1 (es) 2003-07-26
US20160151309A1 (en) 2016-06-02
CY2012022I1 (el) 2015-08-05
BR0213653A (pt) 2004-10-26
JP4758064B2 (ja) 2011-08-24
IL161587A (en) 2009-12-24
MY127797A (en) 2006-12-29
PL216535B1 (pl) 2014-04-30
KR20040047964A (ko) 2004-06-05
US20200038344A1 (en) 2020-02-06
HU230161B1 (en) 2015-09-28
NO2012007I2 (no) 2013-01-02
EP1439829A1 (de) 2004-07-28
ECSP045102A (es) 2004-06-28
PT1439829E (pt) 2005-11-30
CA2464578C (en) 2011-10-11
CY2012022I2 (el) 2015-08-05

Similar Documents

Publication Publication Date Title
IL161587A0 (en) Pharmaceutical containing 3 (3-dimethylamino-1-ethyl-2-methyl-propyl) phenol and providing delayed release of the active ingredient
AU2002349001A1 (en) Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient
HUS1400025I1 (hu) Feniletanolamin-származékok és az ezeket tartalmazó gyógyszerek
HUP0302847A3 (en) Pharmaceutical formulation comprising bicalutamide
IL155293A0 (en) Delayed release pharmaceutical formulations
PT1757606E (pt) Utilização de derivados de xantina como produto farmacêutico, bem como seu processo de preparação
HUP0402113A3 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, preparation and use thereof
HUP0302949A3 (en) Active ingredient combinations comprising insecticidal and acaricidal properties and use thereof
HUP0401911A3 (en) Pesticidal formulations and their use
HUP0303454A3 (en) Solid pharmaceutical composition comprising 4-cyano-trifluoro-3(4-fluorophenyl-sulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and pvp
HUP0500127A3 (en) Novel glycolipid and remedial agent for autoimmune disease containing the same as active ingredient
AU2002327097A1 (en) Novel glycolipid and remedial agent for autoimmune disease containing the same as active ingredient
HUP0303636A3 (en) Dihydronaphthalenederivative compounds and pharmaceutical compositions containing them as active ingredient
IL161902A0 (en) Pharmaceutical formulation comprising bicalutamide
HUP0303260A3 (en) Agrochemical formulations, preparation and use thereof
AU2002340573A8 (en) Powdery active ingredient formulations
GB0119848D0 (en) Delayed and sustained drug release
HUP0202847A3 (en) Synergetic insecticidal and acaricidal active ingredient combinations preparation and use thereof
HUP0401644A3 (en) Aminobenzoephenones, pharmaceutical compositions containing them and use thereof
AU2001267887A1 (en) Medicinal components comprising human parathyroid hormone and medicinal compositions for nasal administration containing the components
HUP0301582A3 (en) Calcilytic compounds and pharmaceutical compositions containing them
IL160886A0 (en) Nicotine containing pharmaceutical formulations and use thereof
IL153176A (en) Phenylpiperazines and pharmaceutical compositions comprising them
AU2002346860A1 (en) Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient
AU2002322424A8 (en) Novel methods and formulations for administration of active agents